ReviewExperimental hematology & oncology2026
Organoids for disease modeling and treatment: state-of-the-art.
Review in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Differentiated SH-SY5Y Model of Hypoxic-Ischaemic Injury Reveals Dynamic Transcriptomic Responses During Reoxygenation.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The emergence of organoids has received widespread attention for faithful recapitulation of physiological and pathological conditions, together with overcoming the major bottleneck of extrapolating laboratory findings from model systems to human organs. Organoid technologies are one of the most revolutionary breakthroughs in the fields of regenerative medicine and biomedical research. These three-dimensional (3D) micro-organ models are derived from stem cells and tissue derivatives, and can highly simulate the structure and function of parental organs, which thus open up unprecedented avenues for understanding organogenesis, disease modeling, drug screening and individualized therapeutics. In this review, we comprehensively elaborate on the core principles and key elements of organoid construction, and the multidisciplinary integration with the advanced technologies. Simultaneously, we systematically summarize their applications in disease modeling and pharmaceutical research, together with the landscape of organoid-based observational and interventional clinical trials in regenerative medicine. Furthermore, we put forward the outstanding prospects and challenges in organoid-based precise diagnosis and treatment applications. In particular, the long-standing key issues in the field such as vascularization and maturity, standardization and reproducibility, biobank and ethical considerations, and the emerging interdisciplinary integrations. Collectively, we outline the state-of-the-art renewal in organoid-guided precision medicine and regenerative medicine, which will benefit the following investigations in development biology and clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.